Drug Trial Radar · NCT06623136
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Actual
Start
Apr 30, 2025
Primary completion
Feb 28, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
Conditions
- Non-Small Cell Lung Cancer
Interventions
ES102Drug
ES102 is administered via intravenous infusion, once every 21 days.
ToripalimabDrug
Toripalimab is administered via intravenous infusion, once every 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) assessed by IRCTime frame: 1-2 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of He'nan University of Science and Technology
Luoyang, China
Shanxi Provincial Cancer Hospital
Taiyuan, China
Taizhou Hospital
Taizhou, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Jilin Cancer Hospital
Changchun, Jilin, China
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.